DV
Dividend Vision

CURX — Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock (CURX)

Total return is -94.6% over the past year, 116.3 points behind SPY at 21.7%. Its deepest 1-year drawdown was 98.0%.

Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company that discovers, develops, and commercializes botanical drugs to treat inflammatory diseases, with a lead candidate called Phyto-N being evaluated for conditions including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company does not currently distribute dividends. This security appeals primarily to investors seeking exposure to early-stage pharmaceutical development rather than current income.

CURX key facts

Asset type
Stock
Asset class
Equity
Inception date
08/26/2025
Last close
$0.22
Market cap
$5,829,705
Average volume
162200.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.02